Paper · 42579020
M2 macrophage-derived exosomal EHF transcriptionally activates FGFR1 to promote malignant phenotypes and glycolysis in NSCLC.
Zhang D and 6 others. J Bioenerg Biomembr, 2026. Cited by 0 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. M2 macrophage-derived exosomal EHF transcriptionally activates FGFR1 to promote malignant phenotypes and glycolysis in NSCLC. Papers, record 42579020. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42579020
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- M2 macrophage-derived exosomal EHF transcriptionally activates FGFR1 to promote malignant phenotypes and glycolysis in NSCLC.
- PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Non-Small-Cell Lung | Major topic |
| Lung Neoplasms | Major topic |
| Exosomes | Major topic |
| Receptor, Fibroblast Growth Factor, Type 1 | Major topic |
| Macrophages | Major topic |
| Humans | |
| Glycolysis | |
| Animals | |
| Mice | |
| Phenotype |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 2022JM-559, 2025JC-YBMS-956 | Natural Science Basic Research Program of Shaanxi Province | PubMed |
Source PubMed
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References36
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36,582,304 | M2-like macrophage-derived exosomes facilitate metastasis in non-small-cell lung cancer by delivering integrin αVβ3. | MedComm (2020) | 2023 | https://conductscience.org/library/papers/36582304 | PubMed |
| 2 | 39,284,119 | Tumor-derived Exosomes and Antitumor Immunity. | J Immunol | 2024 | https://conductscience.org/library/papers/39284119 | PubMed |
| 3 | 28,303,906 | Advances and challenges in targeting FGFR signalling in cancer. | Nat Rev Cancer | 2017 | https://conductscience.org/library/papers/28303906 | PubMed |
| 4 | 32,456,301 | Lung Tumor Cell-Derived Exosomes Promote M2 Macrophage Polarization. | Cells | 2020 | https://conductscience.org/library/papers/32456301 | PubMed |
| 5 | 37,851,210 | M2 Macrophage-Derived Exosomes Regulate miR-199a-3p Promoter Methylation Through the LINC00470-Mediated myc/DNMT3a Axis to Promote Breast Cancer Development. | Biochem Genet | 2024 | https://conductscience.org/library/papers/37851210 | PubMed |
| 6 | 35,020,204 | Cancer statistics, 2022. | CA Cancer J Clin | 2022 | https://conductscience.org/library/papers/35020204 | PubMed |
| 7 | 37,666,899 | M2 macrophage exosomal LINC01001 promotes non-small cell lung cancer development by affecting METTL3 and glycolysis pathway. | Cancer Gene Ther | 2023 | https://conductscience.org/library/papers/37666899 | PubMed |
| 8 | 31,492,847 | Reciprocal regulatory mechanism between miR-214-3p and FGFR1 in FGFR1-amplified lung cancer. | Oncogenesis | 2019 | https://conductscience.org/library/papers/31492847 | PubMed |
| 9 | 35,870,429 | FGFR1 promotes tumor immune evasion via YAP-mediated PD-L1 expression upregulation in lung squamous cell carcinoma. | Cell Immunol | 2022 | https://conductscience.org/library/papers/35870429 | PubMed |
| 10 | 35,806,142 | Characterization of the MicroRNA Cargo of Extracellular Vesicles Isolated from a Pulmonary Tumor-Draining Vein Identifies miR-203a-3p as a Relapse Biomarker for Resected Non-Small Cell Lung Cancer. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/35806142 | PubMed |
1 to 10 of 36
See all 36 referencesCited by0
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.
None in this release.
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| EHF | 26,298 | PubTator's text mining | https://conductscience.org/library/genes/26298 | NCBI Gene |
| FGFR1 | 2,260 | PubTator's text mining | https://conductscience.org/library/genes/2260 | NCBI Gene |
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42579020
GET https://conductscience.org/api/papers/v1/42579020/references?page=2